0
We're unable to sign you in at this time. Please try again in a few minutes.
Retry
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
Retry
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
ARTICLE |

Scharlach: Ätiologie, antitoxische Serumtherapie und Schutzimpfung.

JAMA. 1931;97(21):1560. doi:10.1001/jama.1931.02730210058033.
Text Size: A A A
Published online

ABSTRACT

The purposes of this monograph as stated in the preface are to recommend use of the name Moser-Dick serum instead of Dochez-Dick serum to designate scarlet fever antitoxin, and to orient the physician with regard to recent developments in scarlet fever. The reasons advanced in support of the name Moser-Dick serum are that Moser was the first to attempt to produce a serum specific for scarlet fever and that the Dicks discovered scarlet fever antitoxin and developed a successful method for producing it. American readers who are accustomed to use the serum under its scientific descriptive name, Scarlet Fever Antitoxin, will not understand Kraus's insistence on the hyphenated historical name unless they know of his long association with the State Serum Institute in Vienna, where Moser produced his antistreptococcus serum twenty years ago, when Kraus was an assistant in the institute, of which he later became director. The failure of

Topics

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

First Page Preview

View Large
First page PDF preview

First Page Preview

View Large
First page PDF preview

Figures

Tables

References

CME
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.

Multimedia

Some tools below are only available to our subscribers or users with an online account.

Sign in

Create a free personal account to sign up for alerts, share articles, and more.

Purchase Options

• Buy this article
• Subscribe to the journal

Related Content

Customize your page view by dragging & repositioning the boxes below.

Jobs
brightcove.createExperiences();